Intercure Ltd.INCR

InterCure Ltd. is a small-cap cannabis company trading on NASDAQ, built on a claim of “vertically integrated seed-to-sale” but supplying only ₪270 million of FY2025 revenue-around £53 million at today’s FX-and an official tally of six global brands served through 25 pharmacies. The platform is said to reach “over 100,000 patients” across five territories, yet the only hard figure supplied is revenue, and even that arrives without segment breakdown, net income, or cash flow.

The company’s six brands live on a single product page and a six-image portfolio, while the balance sheet quietly records ₪85 million revenue-₪70.8 million from Israel and €3.4 million (≈₪14.2 million) from Germany-leaving roughly £3.9 million for the other three territories combined. At this scale, the “global” story collapses to a local operation with a handful of export lines. The glossy product photos do not prove distribution breadth; the numbers do not prove scalability.

InterCure’s investor rail supplies FY2025 revenue (₪270 million), a separate ₪85 million revenue figure (Israel and Germany), and a claim of “12 profitable half-years,” yet no income statement, no EPS, no operating or free cash flow, no diluted share count, and no buyback data. The rail does not parse inventory, receivables, or capex, so the profit claim remains an assertion rather than a filing. The company’s “Explore Our Brands” page shows six product images; the “About” page shows ₪85 million revenue; the “Official source page” shows ₪270 million revenue for FY2025. Choose your anchor; the rest is silence.

For context, InterCure lists on NASDAQ under the ticker INCR. The official site does not supply a chart route, so readers must source price context externally. The company’s own rails do not provide liquidity depth, order-book levels, or trading volumes, leaving the market mechanism opaque to anyone relying solely on the issuer’s pages.

What changed this week: no new earnings release, no 8-K, no product approval, no regulatory filing beyond the existing rails. The issuer’s investor rail repeats the same six figures without new filings or clarifications. The operating story remains: six brands, 25 pharmacies, ₪270 million revenue for FY2025, ₪85 million revenue from Israel and Germany, and a promise of “international growth” without numbers to back it.

What remains unproven: segment margins, cash generation, working capital, leverage, R&D spend, capex, share dilution, and any audited financials. The issuer’s rails do not supply these, so any claim beyond the six provided figures is aspirational rather than evidenced. The tension sits between the polished brand page and the skeletal balance sheet-until InterCure files a full income statement, the “profitable half-years” claim cannot be verified, and the global platform story cannot be trusted.

Next evidence that would deepen the file: an audited annual report (Form 20-F or 10-K equivalent), a quarterly cash-flow statement, a segment breakdown of the ₪270 million revenue, and any 8-K disclosing material contracts, regulatory approvals, or changes in control. Absent those, the file rests on the six provided figures and the gap between the brand story and the balance sheet.